<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="tbl0005">
 <label>Table 1</label>
 <caption>
  <p>Summary of potential peptide therapies for Influenza.</p>
 </caption>
 <alt-text id="at0015">Table 1</alt-text>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th align="left">Target protein</th>
    <th align="left">Peptide Name</th>
    <th align="left">Sequence</th>
    <th align="left">Derived from</th>
    <th align="left">IC
     <sub>50</sub>
    </th>
    <th align="left">Assay Format Tested</th>
    <th align="left">Phase</th>
    <th align="left">Reference</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="left" valign="middle" rowspan="12">
     <bold>HA</bold>
    </td>
    <td align="left">LL-37</td>
    <td align="left">LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES</td>
    <td align="left">Cathelicidin</td>
    <td align="left">0.9−11.3 μM</td>
    <td align="left">Neutralization assay</td>
    <td align="left">Pre-clinical</td>
    <td align="left" valign="middle" rowspan="2">[
     <xref rid="bib0985" ref-type="bibr">197</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">GI-20</td>
    <td align="left">GIKEFKRIVQRIKDFLRNLV</td>
    <td align="left">AMP (LL-37)</td>
    <td align="left">1.6−3.2 μM</td>
    <td align="left">Neutralization assay</td>
    <td align="left">Pre-clinical</td>
   </tr>
   <tr>
    <td align="left">P1, P2, P3</td>
    <td align="left">SKHSSLDCVLRP (1), AGDDQGLDKCVPNSKEK (2), and NGESSADWAKN (3)</td>
    <td align="left">Lactoferrin</td>
    <td align="left">PM-FM</td>
    <td align="left">Neutralization assay</td>
    <td align="left">Pre-clinical</td>
    <td align="left">[
     <xref rid="bib0035" ref-type="bibr">7</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" rowspan="3">Tetrapeptides</td>
    <td align="left">Peptide 14 (VLRP)</td>
    <td align="left">Lactoferrin</td>
    <td align="left" valign="middle" rowspan="3">fM range</td>
    <td align="left" valign="middle" rowspan="3">Neutralization assay</td>
    <td align="left" valign="middle" rowspan="3">Pre-clinical</td>
    <td align="left" valign="middle" rowspan="3">[
     <xref rid="bib0920" ref-type="bibr">184</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">Peptide 15 (SLDC) and</td>
    <td align="left" valign="middle" rowspan="2">SKHSSLDCVLRP (1),</td>
   </tr>
   <tr>
    <td align="left">Peptide 17 (SKHS)</td>
   </tr>
   <tr>
    <td align="left">P9</td>
    <td align="left">NGAICWGPCPTAFRQIGNCGHFKVRCCKIR</td>
    <td align="left">mouse β-defensin-4</td>
    <td align="left">1.5−4.8 μg/mL</td>
    <td align="left">plaque reduction assay</td>
    <td align="left">Pre-clinical</td>
    <td align="left">[
     <xref rid="bib1155" ref-type="bibr">231</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">EB</td>
    <td align="left">RRKKAAVALLPAVLLALLAP</td>
    <td align="left">fibroblast growth factor 4</td>
    <td align="left">3−10 μM</td>
    <td align="left">hemagglutination inhibition assay</td>
    <td align="left">Pre-clinical</td>
    <td align="left">[
     <xref rid="bib0530" ref-type="bibr">106</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">FP-4</td>
    <td align="left">RRKKWLVFFVIFYFFR</td>
    <td align="left">Tyrosine kinase inhibitor peptide</td>
    <td align="left">0.05−0.13 μM</td>
    <td align="left">plaque-reduction assay</td>
    <td align="left">Pre-clinical</td>
    <td align="left">[
     <xref rid="bib0025" ref-type="bibr">5</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">Flufirvitide-3</td>
    <td align="left">- *</td>
    <td align="left">fusion initiation region</td>
    <td align="left">nM range</td>
    <td align="left">plaque inhibition assay</td>
    <td align="left">Phase 1</td>
    <td align="left">[
     <xref rid="bib0335" ref-type="bibr">67</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">P7</td>
    <td align="left">(Nva-Orn-
     <sup>me</sup>LEY
     <sup>chl</sup>FEWLS-βAla
    </td>
    <td align="left">Neutralizing antibodies</td>
    <td align="left">30−70 nM</td>
    <td align="left">AlphaLisa competition binding assay</td>
    <td align="left">Pre-clinical</td>
    <td align="left">[
     <xref rid="bib0540" ref-type="bibr">108</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">C-18-s2(1−5)</td>
    <td align="left">C
     <sub>17</sub>H
     <sub>35</sub>CO-ARLPR-NH
    </td>
    <td align="left">Phage library</td>
    <td align="left">1.6−1.9 μM</td>
    <td align="left">plaque inhibition assay</td>
    <td align="left">Pre-clinical</td>
    <td align="left">[
     <xref rid="bib0685" ref-type="bibr">137</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" rowspan="2">
     <bold>NA</bold>
    </td>
    <td align="left">peptide P</td>
    <td align="left">PGEKGPSGEAGTAGPPGTPGPQGL</td>
    <td align="left">Cod skin hydrolysates</td>
    <td align="left">3.5 mg/mL</td>
    <td align="left">NA inhibitory assay</td>
    <td align="left">Pre-clinical</td>
    <td align="left">[
     <xref rid="bib0590" ref-type="bibr">118</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">P2</td>
    <td align="left">errKPAQP</td>
    <td align="left">Binding pockets of oseltamivir in NA</td>
    <td align="left">4.25 μM</td>
    <td align="left">NA inhibitory assay Cytopathic effect (CPE) assay</td>
    <td align="left">Pre-clinical</td>
    <td align="left">[
     <xref rid="bib0170" ref-type="bibr">34</xref>]
    </td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn>
   <p>*not available in the literature.</p>
  </fn>
 </table-wrap-foot>
</table-wrap>
